APP and Alzheimer disease: In Alzheimer’s disease and other tauopathies, dysregulation of these enzymes and pathways alters glycosylation homeostasis, thereby influencing APP metabolism, tau aggregation, receptor signaling, and neuroinflammation [1,50,57].